Sangamo Therapeutics (SGMOQ) EBITDA Margin (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted EBITDA Margin of 268.51% for Q4 2025, up 95.61% on a QoQ basis from 6119.28% in Q3 2025, and up 13134.0% year-over-year from N/an in Q4 2024.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) EBITDA Margin (2010 - 2025) Analysis & Trends
Sangamo Therapeutics has reported EBITDA Margin for 16 years, with the latest figure at 268.51% in Q4 2025.
- On a quarterly basis, EBITDA Margin rose 13134.0% year-over-year to 268.51% in Q4 2025; TTM through Dec 2025 was 306.53%, a 12332.0% decrease from a year earlier, with the FY2025 full-year figure at 306.53%, down 12665.0% from the prior year.
- EBITDA Margin was 268.51% for Q4 2025 at Sangamo Therapeutics, up from 6119.28% in the prior quarter.
- The five-year high for EBITDA Margin was 21.52% in Q3 2024, with the low at 10712.27% in Q1 2024.
- Average EBITDA Margin over 5 years is 1790.54%, with a median of 205.44% recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin tumbled 1072368 bps in 2024, then soared 1031932 bps in 2025.
- Over 5 years, EBITDA Margin stood at 142.57% in 2021, then tumbled by 43 bps to 203.42% in 2022, then tumbled by 1394 bps to 3039.13% in 2023, then soared by 87 bps to 399.85% in 2024, then soared by 33 bps to 268.51% in 2025.
- The last three EBITDA Margin figures came in at 268.51% (Q4 2025), 6119.28% (Q3 2025), and 97.54% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.80 Bn | 3.50 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.04 Bn | 3.04 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.64 Bn | 2.64 Bn | - | -25,827.14% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.98 Bn | 1.82 Bn | 56.40 Mn | 0.56% |
| 10 | Sangamo Therapeutics | 43.99 Mn | 23.04 Mn | - | -268.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -268.51% |
| Sep 30, 2025 | -6,119.28% |
| Jun 30, 2025 | -97.54% |
| Mar 31, 2025 | -460.28% |
| Dec 31, 2024 | -399.85% |
| Sep 30, 2024 | 21.52% |
| Jun 30, 2024 | -10,416.85% |
| Mar 31, 2024 | -10,712.27% |
| Dec 31, 2023 | -3,039.13% |
| Sep 30, 2023 | -1,132.24% |
| Jun 30, 2023 | -1,807.93% |
| Mar 31, 2023 | 11.42% |
| Dec 31, 2022 | -203.42% |
| Sep 30, 2022 | -207.46% |
| Jun 30, 2022 | -155.67% |
| Mar 31, 2022 | -160.32% |
| Dec 31, 2021 | -142.57% |
| Sep 30, 2021 | -169.58% |
| Jun 30, 2021 | -174.73% |
| Mar 31, 2021 | -176.19% |